Long-term data from studies in established relapsing-remitting MS (RRMS)


 

The original BETAFERON pivotal trial led to the approval of BETAFERON in RRMS [1-3]. In the 16- and 21-year long-term follow-up (LTF) studies, patients who participated in the original BETAFERON pivotal trial were re-evaluated [4,5].

  • The 16-year LTF assessed long-term clinical outcomes and explored the relationship between drug exposure and long-term disability. The ascertainment rate in this study was 88% [4,5].
  • The 21-year LTF primarily aimed to determine the vital status of the participants of the original BETAFERON pivotal study. The vital status was assessed in 98.4% (366/372) of the original study participants [6].

 

Alt tag

Patients enrolled in the original BETAFERON pivotal trial were re-evaluated in the 16- and 21-year long-term follow-up studies [4-6]

 

 

 

Outcomes from the 16-year LTF

Vital status at the 21-year LTF

References

Alt tag